As our work progresses, we believe that the clinical success of the CRISPR/Cas9 system will depend upon the development of effective delivery methods. Our strategy is to undertake parallel efforts on in vivo and ex vivo delivery. To do so, in January of 2016, we created a new division called eXtellia Therapeutics focused on the application of CRISPR/Cas9 genome editing in the fields of immuno-oncology and autoimmune and inflammatory diseases. Intellia will maintain a focus on in vivo applications. We believe this unique approach provides Intellia with a competitive advantage as we pursue our overall goal of maximizing the true potential of CRISPR/Cas9.
Our sentinel ex vivo programs will help inform the broader applicability of CRISPR/Cas9 by eXtellia. We expect eXtellia to focus on other relevant types of immune cells, such as natural killer, or NK cells, and tumor infiltrating lymphocytes, or TILs, for immuno-oncology applications, T regulatory cells, or Tregs, for autoimmune disorders and other cell types, including induced pluripotent stem cells, mesenchymal stem cells and muscle satellite stem cells for tissue-targeted treatments.
|Immuno-oncology Opportunity||Autoimmune and Inflammatory Disease (AIID) Opportunity|